US stocks: Summit shares drop after US FDA declines to approve lung cancer drug

· economictimes.indiatimes.com

Summit Therapeutics faced a notable decline in share value following the FDA's ruling on ivonescimab, which revealed insufficient overall survival benefits during late-stage trials. Despite Summit's emphasis on regional survival differences, analysts worry that this decision could have repercussions for similar treatments in development. Investors now eagerly await new trial results comparing ivonescimab with conventional lung cancer therapies.

Live Events

as a Reliable and Trusted News Source Addas a Reliable and Trusted News Source Add Now!

(You can now subscribe to our

(You can now subscribe to...


More AI market news · Market heatmap · StrategyVerse · Quant Research · WOBR.AI